TWO-YEAR EFFICACY AND SAFETY OF GUSELKUMAB FOR TREATMENT OF MODERATE-TO-SEVERE PSORIASIS: PHASE 3 VOYAGE 1 TRIAL

被引：3
|
作者：
Griffiths, C. E. [1 ]
Papp, K. A. [2 ]
Kimball, A. B. [3 ]
Randazzo, B. [4 ]
Wasfi, Y. [4 ]
Li, S. [4 ]
Shen, Y. -K. [4 ]
Blauvelt, A. [5 ]
机构：
[1] Univ Manchester, Manchester, Lancs, England
[2] K Papp Clin Res & Prob Res Inc, Waterloo, ON, Canada
[3] Beth Israel Deaconess Med Ctr Inc, Harvard Med Fac Phys, Boston, MA USA
[4] Janssen Res & Dev LLC, Spring House, PA USA
[5] Oregon Med Res Ctr, Portland, OR USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2018年 / 77卷
关键词：
D O I：
10.1136/annrheumdis-2018-eular.5825
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0912
引用
收藏
页码：1580 / 1581
页数：3
相关论文
共 50 条
  • [21] Dupilumab Efficacy and Safety in Children with Uncontrolled, Moderate-to-Severe Asthma: The Phase 3 VOYAGE Study
    Bacharier, L. B.
    Maspero, J. F.
    Katelaris, C. H.
    Fiocchi, A. G.
    Gagnon, R.
    de Mir, I
    Jain, N.
    Sher, L. D.
    Mao, X.
    Liu, D.
    Zhang, Y.
    Khan, A. H.
    Kapoor, U.
    Khokhar, F. A.
    Rowe, P.
    Deniz, Y.
    Ruddy, M.
    Laws, E.
    Amin, N.
    Mannent, L. P.
    Lederer, D. J.
    Hardin, M.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 203 (09)
  • [22] Efficacy and safety of guselkumab for the treatment of patients with moderate-to-severe plaque psoriasis: A meta-analysis of randomized clinical trials
    Tao, Xing-Bao
    Huang, Yin-Qiu
    Zhou, Yi-Hong
    Zhang, Lv-Lang
    Chen, Yao-Kai
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2020, 19 (02) : 433 - 440
  • [23] Efficacy and safety of ustekinumab in the treatment of patients affected by moderate-to-severe psoriasis
    Talamonti, M.
    Galluzzo, M.
    Teoli, M.
    Bavetta, M.
    Chimenti, S.
    Costanzo, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2011, 165 (06) : E34 - E34
  • [24] Maintenance of response after guselkumab withdrawal in patients with moderate-to-severe psoriasis: A post hoc analysis of the VOYAGE 2 trial
    Conrad, Curdin
    Koerber, Andreas
    Schaekel, Knut
    Thaci, Diamant
    Joks, Gero
    Jazra, Maria
    Wegner, Sven
    Wapenaar, Robert
    Paul, Carle
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB107 - AB107
  • [25] Efficacy and safety of infliximab biosimilars in the treatment of patients with moderate-to-severe psoriasis
    Chasapi, Vasiliki
    Routsi, Eleni
    Lantzou, Sotiria
    Papoutsaki, Marina
    Panagakis, Pantelis
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [26] Patient-reported symptoms and signs of moderate-to-severe psoriasis treated with guselkumab or adalimumab: results from the randomized VOYAGE 1 trial
    Papp, K. A.
    Blauvelt, A.
    Kimball, A. B.
    Han, C.
    Randazzo, B.
    Wasfi, Y.
    Shen, Y. -K.
    Li, S.
    Griffiths, C. E. M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (09) : 1515 - 1522
  • [27] Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis
    Mastorino, Luca
    Siliquini, Niccolo
    Avallone, Gianluca
    Ortoncelli, Michela
    Quaglino, Pietro
    Dapavo, Paolo
    Ribero, Simone
    DERMATOLOGY REPORTS, 2022, 14 (03)
  • [28] Efficacy and Safety Analysis in Chinese Patients with Moderate-to-Severe Psoriasis from a Phase 3 Trial: Impact of Treatment Withdrawal and Retreatment of Ixekizumab
    Gao, Xinghua
    Pan, Weili
    Zheng, Min
    Li, Fuqiu
    Dong, Xiuqin
    Lv, Dong
    Guo, Zaipei
    Li, Jinnan
    Wang, Xuan
    Geng, Songmei
    ADVANCES IN THERAPY, 2025, 42 (01) : 334 - 347
  • [29] Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials
    Puig, L.
    Tsai, T. -F.
    Bhutani, T.
    Uy, J.
    Ramachandran, P.
    Song, M.
    You, Y.
    Gooderham, M.
    Lebwohl, M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2020, 34 (08) : 1744 - 1749
  • [30] Maintenance of complete skin clearance throughout 3 years of continuous guselkumab treatment in patients with moderate-to-severe psoriasis: A post hoc analysis of 5-year data from the VOYAGE 1 trial
    Costanzo, Antonio
    Conrad, Curdin
    Gramiccia, Talia
    Jazra, Maria
    de Jong, Elke M. G. J.
    Iversen, Lars
    Ozturk, Bulent
    Wapenaar, Robert
    Wegner, Sven
    Torres, Tiago
    Puig, Luis
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB108 - AB108
12345